Brokerage firms like Macquarie have assigned an underperform and an outperform rating to United Spirits and HDFC Bank, while UBS has maintained its buy rating on HDFC Bank. Meanwhile, UBS also has a buy view on ICICI Bank, and Morgan Stanley has an equal-weight rating on PB Fintech.We have collated a list of recommendations from top brokerage firms from ETNow and other sources:Macquarie on United Spirits: Underperform | Target price: Rs 1,100Macquarie has maintained an underperform rating on United Spirits with a target price of Rs 1,100.Flattish demand trends and muted volume growth are likely in Q2. The global brokerage firm expects 5% sales growth and 6% EBITDA growth in Q2. Prestige volumes are expected to be flat year-over-year, while continued strength in the luxury segment should support realizations.Macquarie on HDFC Bank: Outperform | Target price: Rs 1,900Macquarie has maintained an outperform rating on HDFC Bank with a target price of Rs 1,900.Reported profits are expected to be weak year-over-year, but net interest income (NII) growth is projected at 14% YoY, while net interest margins (NIMs) expanded by 5 basis points quarter-over-quarter to 3.52%. Deposit growth is estimated to see an increase of around Rs 800 billion QoQ. Loan growth is likely to remain weak at 8% YoY due to sell-downs and the base effect.UBS on HDFC Bank: Buy | Target price: Rs 1,900UBS has maintained a buy rating on HDFC Bank, increasing the target price to Rs 2,100 from Rs 1,900.Loan book rebalancing is likely to aid in ROA acceleration, and a favorable rate environment over the next two years will support faster repricing of liabilities. However, softer near-term loan growth may limit NII acceleration. Retail deposits and NIM progression are expected to be key catalysts.UBS on ICICI Bank: Buy | Target price: Rs 1,575UBS has maintained a buy rating on ICICI Bank and raised the target price to Rs 1,575 from Rs 1,300. UBS believes that the bank's consistent performance will support premium valuations, alongside stable metrics and healthy return ratios, which are expected to drive stock performance. While growth is likely to moderate in the near term, the bank's asset quality and high provisions buffer remain relatively strong.Morgan Stanley on PB Fintech: Equal-weight | Target price: Rs 1,375Morgan Stanley has maintained an equal-weight rating with a target price of Rs 1,375.The recent news regarding entry into the healthcare sector is a key concern for investors, particularly regarding whether this will change the asset-light nature of the business. It is premature to assess the potential financial impact. Investor sentiment will be influenced by the magnitude of the capital outlay—whether it is one-time or recurring—as well as whether it involves a solo venture or multiple partners, and what the company envisions as benefits to revenue and insurer-partner relationships.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)